Director / Senior Director, Clinical Scientist (Part-time, Temp)
Boost your chances before you apply.
Superluminal Medicines, Inc.
Boston, MA, US
Summary
The Clinical Scientist will lead the scientific design, execution, and data-driven evaluation of clinical trial programs. Responsibilities include authoring key clinical documents, conducting medical data reviews, and serving as a scientific liaison for cross-functional teams.
Job Description
About Superluminal Medicines:
Superluminal Medicines is a generative biology and chemistry company revolutionizing the speed and accuracy of how small molecule medicines are created. The Company’s platform aims to create candidate-ready compounds with unprecedented speed using a combination of deep biology, computational and medicinal chemistry, machine learning, and proprietary big data infrastructure. We are expanding the team of talented scientists who seek to build the future of small molecule drug discovery with creativity and innovation.
The Role
Superluminal Medicines is seeking a detail-oriented and collaborative Clinical Scientist to join our team 15-20 hours per week. Reporting directly to the Executive Director of Clinical Development, you will play a critical role in the scientific design, execution, and data-driven evaluation of our clinical trial programs.
You will serve as a core scientific engine within the clinical team, bridging the gap between non-clinical findings and clinical execution. Your work will directly shape protocol design, safety monitoring, data analysis, and the synthesis of scientific evidence to advance our pipeline through Phase I–IV trials safely and effectively.
Key Responsibilities
- Protocol & Document Authoring: Author and review key clinical trial documents, including but not limited to Clinical Study Protocols (CSPs), Investigator’s Brochures (IBs), Clinical Study Reports (CSRs), and Informed Consent Forms (ICFs).
- Clinical Data Review & Signal Evaluation: Lead ongoing scientific and medical data review, analyzing emerging safety signals, evaluating lab trends, assessing protocol compliance, and drafting data summaries for medical oversight.
- Trial Design & Endpoint Strategy: Conduct literature reviews and evaluate clinical data to support scientific rationales, select robust primary/secondary/exploratory study endpoints, and refine study design strategies.
- Cross-Functional Partnership: Serve as the primary scientific liaison for clinical trial site/s, CROs, and external investigators while collaborating closely with Medical Directors, Clinical Operations, Clinical Pharmacology, Biostatistics, and Regulatory Affairs.
- Regulatory & Scientific Dissemination: Author and review clinical components of regulatory submissions (INDs, CTAs, NDAs/BLAs) and contribute to scientific abstracts, manuscripts, and conference presentations.
- Governance & Oversight: Prepare for and present scientific data during Data Safety Monitoring Board (DSMB) meetings, Advisory Board meetings, and Investigator Meetings.
Qualifications
- Education: Scientific degree (BS), Advanced degree preferred (MS, PharmD or equivalent) in Biology, Immunology, Biochemistry, Pharmacology, Pharmaceutical Sciences, or a related scientific/healthcare field.
- Experience: 8+ years of clinical research experience within the biopharmaceutical industry, CROs, or academic clinical trial centers, with a track record of supporting trial execution.
- Expertise: Deep understanding of clinical trial methodology, biostatistical concepts, GCP/ICH guidelines, and medical data review tools (e.g., Spotfire, JReview, Medidata Rave).
- Communication: Exceptional oral and written communication skills, with a proven ability to translate complex clinical data into clear scientific documents and stakeholder presentations.
- Mindset: A collaborative and adaptable team player who thrives in a fast-paced environment and excels at managing cross-functional dependencies.
Benefits:
Superluminal offers a comprehensive benefits package that fully covers employees’ annual deductibles and monthly premiums for medical, dental, and vision insurance. The package also includes a 401(k) match program, a Massachusetts transportation subsidy, equity, unlimited paid time off, and both disability and life insurance.
Equal Opportunity Statement:
Superluminal Medicines is an Equal Opportunity Employer committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status.
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.
Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability.
With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP.
Company size
11-50 employees
Industry
Biotechnology Research
Org type
Privately Held
Headquarters
Boston, Massachusetts
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.
Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability.
With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP.
Company size
11-50 employees
Industry
Biotechnology Research
Org type
Privately Held
Headquarters
Boston, Massachusetts